|Articles|September 4, 2013

Examining Containment Strategies in High Potency Manufacturing

With the increasing use of high-potency APIs, it is more important than ever to have an appropriate containment strategy to protect both the quality of your product and the safety of your personnel.

With the increasing use of high-potency APIs, it is more important than ever to have an appropriate containment strategy to protect both the quality of your product and the safety of your personnel. Many important questions should be asked. Have you considered environmental, health, and safety (EH&S) issues early in your product development process? What are OELs and how should you evaluate industrial hygiene exposure? How can you prevent exposure? What elements are crucial for containment?

To examine these questions and others, Pharmaceutical Technology will host a complimentary, educational, live webcast, Containment Strategies in High-Potency Manufacturing, on Thursday, September 12 at 11:00 AM EDT. This 30-minute webcast will focus on current best practices and strategies for containment in high-potency manufacturing.

The webcast will be presented by John Farris, a Certified Industrial Hygienist and president & CEO of SafeBridge Consultants.  John is a recognized expert in the safe handling of potent pharmaceutical compounds.

Audience members will be able to ask questions for additional insight during the live webcast on Thursday, September 12. Additional information and registration for the live webcast and on-demand viewing may be found at www.pharmtech.com/highpotency.


Related to this article

Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
AAPS PharmSci 360: CMC Strategies, Part 3
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.